Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101

Life Science Investing News

Aimmune Therapeutics (Nasdaq:AIMT) a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the initiation of a phase 2 study, with Regeneron and Sanofi, of AR101 with adjunctive dupilumab in peanut-allergic patients. As quoted in the press release: AR101 is Aimmune’s investigational biologic oral immunotherapy for desensitization of patients with peanut allergy, and dupilumab …

Aimmune Therapeutics (Nasdaq:AIMT) a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the initiation of a phase 2 study, with Regeneron and Sanofi, of AR101 with adjunctive dupilumab in peanut-allergic patients.

As quoted in the press release:

AR101 is Aimmune’s investigational biologic oral immunotherapy for desensitization of patients with peanut allergy, and dupilumab is Regeneron and Sanofi’s fully human monoclonal antibody that inhibits signaling of IL-4 and IL-13 cytokines, which are believed to be major drivers of type 2 inflammation. Aimmune is providing clinical supply of AR101, as well as food challenge materials, for the Regeneron-sponsored study.

“We are delighted to have Regeneron and Sanofi join us in our commitment to improve the lives of people with food allergies,” said Jayson Dallas, M.D., President and CEO of Aimmune. “Through this exciting collaboration, we can look at the potential to improve desensitization with adjunctive use of dupilumab. This collaboration is part of our ongoing effort to further and continuously characterize AR101 as the cornerstone of the platform for desensitization.”

Click here to read the full press release.

The Conversation (0)
×